Read the record behind the answer.

Begin with the substance in the paper

The FDA’s TB-500 review is the central record for the identity and evidence gaps discussed here. It says TB-500 and full-length thymosin beta-4 are different substances.

No report of a person receiving TB-500 appeared in the reviewed medical literature checked September 30, 2026.

For a paper cited in an offer, write down the substance, the setting and what was measured. Compare that with the exact claim. Keep any mismatch in the margin rather than smoothing it away.

Keep a record’s date with its meaning

The FDA ingredient page marked current April 22, 2026 shows that a request to consider TB-500 for pharmacy preparation was taken back by the person who sent it. This did not approve TB-500. The page leaves out the date when its sender took the request back.

At the September 30, 2026 check, FDA staff had proposed against listing TB-500, and no FDA record of the advisory committee’s votes had been posted.

Read results and limits together

The related human studies tested the whole thymosin beta-4 protein, a different substance from TB-500. In the dry-eye report, the main results for eye discomfort and eye-surface damage showed no clear difference from comparison drops. In the skin-gel study records, similar shares of sores closed with treatment and comparison gels. Those records did not report whether a difference between groups could be due to chance.

Checking whether a difference between groups could be due to chance is called a statistical comparison. When the record does not provide that comparison, keep the limit alongside the result.

Take the disputed claim back to care

You do not have to read an entire field to ask a useful question. Take the source and the offer together. Ask the clinician to explain how the cited result supports the decision being proposed for you.